<SEC-DOCUMENT>0000950170-24-060452.txt : 20240515
<SEC-HEADER>0000950170-24-060452.hdr.sgml : 20240515
<ACCEPTANCE-DATETIME>20240515161016
ACCESSION NUMBER:		0000950170-24-060452
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20240515
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240515
DATE AS OF CHANGE:		20240515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Athira Pharma, Inc.
		CENTRAL INDEX KEY:			0001620463
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				453368487
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39503
		FILM NUMBER:		24950668

	BUSINESS ADDRESS:	
		STREET 1:		18706 NORTH CREEK PARKWAY, SUITE 104
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98011
		BUSINESS PHONE:		(425) 620-8501

	MAIL ADDRESS:	
		STREET 1:		18706 NORTH CREEK PARKWAY, SUITE 104
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98011

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	M3 Biotechnology, Inc.
		DATE OF NAME CHANGE:	20140924
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>atha-20240515.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-05-15T13:37:32.9034+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:atha="http://athira.com/20240515" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_750cf112-c6ce-4a57-9266-f8e471629b65" name="dei:EntityCentralIndexKey" contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf">0001620463</ix:nonNumeric><ix:nonNumeric id="F_17f444c2-960c-4f03-8112-8f34fef0c858" name="dei:AmendmentFlag" contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf" format="ixt:fixed-false">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="atha-20240515.xsd"/></ix:references><ix:resources><xbrli:context id="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-15</xbrli:startDate><xbrli:endDate>2024-05-15</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;min-height:0.6in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:'Wingdings',serif;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="agm_results"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Washington, DC 20549</span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c48af838-f186-4bc9-b334-e43df2fb570a" contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b4a020e8-5153-4f88-98e7-04b881c89c9e" contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">May 15, 2024</span></ix:nonNumeric></span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dff8c163-1823-451e-ab43-d030dd36556c" contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">Athira Pharma, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.34%;"/>
    <td style="width:33.34%;"/>
    <td style="width:33.32%;"/>
   </tr>
   <tr style="height:13.7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span><ix:nonNumeric id="F_d24a057e-4bd5-4d3f-bd6f-d612bf3f986f" contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span><ix:nonNumeric id="F_c3fe8820-5adc-4dc9-96c3-614dfad52ce7" contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">001-39503</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span><ix:nonNumeric id="F_e78f1d15-e0a1-411b-a117-d17aae3466f6" contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">45-3368487</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:20.15pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or other jurisdiction</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">of incorporation)</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Commission</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">File Number)</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(IRS Employer</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1c1d385c-f806-4b1f-a337-276b6d6a6c10" contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18706 North Creek Parkway</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_72a01358-2879-410e-a3f6-d183a6042353" contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Suite 104</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5586779e-1185-4c5a-8a64-daf021d1f8b8" contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Bothell</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_033246c2-0b75-480e-b479-0c60d5f842f2" contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">WA</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3bb5e9ae-fb97-42fd-a935-03038a6c13f7" contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">98011</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Address of principal executive offices, including zip code)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d6f55983-208f-4f77-928a-c953563d3f07" contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">425</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8a5ab1c7-e6ed-4f96-a5fd-e59f66e36108" contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">620-8501</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Registrant&#8217;s telephone number, including area code)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Former name or former address, if changed since last report)</span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:3.016%;"/>
    <td style="width:96.984%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_559186fd-8acd-4224-9ef7-7330efd43813" contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_2a184cd2-9cbd-43a1-b57c-235a4cb8a2dd" contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_403f0323-7b93-4e01-8332-c5f927558553" contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_1b5e8d94-039f-4bff-9a83-6723d444d75d" contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:35%;"/>
    <td style="width:30%;"/>
    <td style="width:35%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_fc20adb2-720f-47a2-b1d4-d871a8e287ab" contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_bd72a9b4-c4cc-472d-9cd9-ecf0f03e0cbc" contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ATHA</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_e92e58df-0b6e-45ab-8e81-8e34ca27a2d3" contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;<br/>(The Nasdaq Global Select Market)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:25%;"/>
    <td style="width:75%;"/>
   </tr>
   <tr style="height:15.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emerging Growth Company</span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_507f6bc2-2839-4240-864a-7db7feffcb5b" contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act).  </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3122370b-eb6d-4013-acfc-c91e493eb9ad" contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:'Wingdings',serif;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.6in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.6in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 15, 2024, Athira Pharma, Inc. (the &#8220;Company&#8221;) issued a press release reporting its financial results for the quarter ended March 31, 2024. A copy of the press release is furnished herewith as Exhibit 99.1.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tem 7.01 Regulation FD Disclosure.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company announces material information to the public through a variety of means, including filings with the Securities and Exchange Commission, press releases, public conference calls, the Company&#8217;s website (www.athira.com), its investor relations website (investors.athira.com), and its news site (investors.athira.com/news-and-events/press-releases). The Company uses these channels, as well as social media, including its X account (formerly known as Twitter)(@athirapharma), LinkedIn account (www.linkedin.com/company/athirapharma), Instagram account (@athirapharma) and Facebook page (www.facebook.com/athirapharmainc), to communicate with investors and the public about the Company, its product candidates, and other matters. Therefore, the Company encourages investors, the media, and others interested in the Company to review the information it makes public in these locations, as such information could be deemed to be material information.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d) Exhibits.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9%;"/>
    <td style="width:1%;"/>
    <td style="width:90%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.042in;vertical-align:bottom;border-bottom:1pt solid;padding-right:0.028in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit No.</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;border-bottom:1pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;border-bottom:1pt solid;padding-right:0.028in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99.1</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="atha-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Athira Pharma, Inc. press release dated May 15, 2024</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.028in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (formatted as Inline XBRL)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information furnished in this Current Report under Items 2.02 and 7.01 and the exhibit attached hereto shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.6in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.6in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:5%;"/>
    <td style="width:45%;"/>
    <td style="width:5%;"/>
    <td style="width:45%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.042in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Athira Pharma, Inc.</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;padding-right:0.042in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 15, 2024</span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;border-bottom:1pt solid;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Mark Litton</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.042in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mark Litton</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.042in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.6in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>atha-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Exhibit 99.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img247042425_0.jpg" alt="img247042425_0.jpg" style="width:174px;height:86px;">&#160;</p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:14pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:14pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Topline data from Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer&#x2019;s disease expected in second half of 2024</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Submitted Investigational New Drug application to U.S. Food and Drug Administration for ATH-1105 for the treatment of amyotrophic lateral sclerosis; On track to dose subjects in a first-in-human study in second quarter of 2024</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Strong balance sheet to support innovative pipeline through key clinical inflection points</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">BOTHELL, Wash., May 15, 2024 &#x2013; Athira Pharma, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended March 31, 2024, and provided recent pipeline and business updates.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;We are on the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">cusp of a potentially transformative milestone as we are fast approaching the expected topline data readout from our Phase 2/3 LIFT-AD clinical trial of fosgonimeton in Alzheimer&#x2019;s disease (AD) in the second half of this year,&#x201d; said Mark Litton, Ph.D., President and Chief Executive Officer of Athira. &#x201c;The totality of clinical and nonclinical data to date support our confidence in the LIFT-AD trial and underscore the potential of our differentiated approach in targeting the neurotrophic HGF system to induce neuroprotective effects across a number of neurodegenerative diseases.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;We were delighted to welcome Javier San Martin, M.D. as our new Chief Medical Officer. His insight and expertise will be invaluable as we move toward the LIFT-AD data readout and the potential opportunity to deliver fosgonimeton as a new treatment option for AD patients in need of better therapies. In parallel, we continue to progress ATH-1105 in amyotrophic lateral sclerosis (ALS) and expect to initiate a first-in-human study of this oral small molecule drug candidate in the coming months,&#x201d; added Dr. Litton.</font></p>
  <p style="font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Clinical Development &amp; Pipeline Programs</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Athira&#x2019;s drug development pipeline includes potential first-in-class (fosgonimeton) and next-generation (ATH-1105 and ATH-1020) small molecule drug candidates designed to promote the neurotrophic hepatocyte growth factor (HGF) system, which activates neuroprotective, neurotrophic and anti-inflammatory pathways in the central nervous system. Athira&#x2019;s drug candidates have distinct properties, which the Company believes may be applicable to a broad range of neurodegenerative diseases.</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Fosgonimeton (ATH-1017)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> &#x2013; A potentially first-in-class, once daily, subcutaneously administered drug candidate initially targeted for the potential treatment of Alzheimer&#x2019;s disease.</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">LIFT-AD Phase 2/3 clinical trial of fosgonimeton in mild-to-moderate Alzheimer&#x2019;s disease </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">(</font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">NCT04488419</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Athira expects to report topline data from LIFT-AD in the second half of 2024. </font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In January 2024, Athira announced the completion of enrollment of the LIFT-AD study.</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The LIFT-AD study is investigating the effects of fosgonimeton 40 mg compared with placebo in mild-to-moderate AD patients who are not receiving background therapy.  The primary endpoint is the Global Statistical Test (GST),</font><font style="color:#222222;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> combining the results from </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">the co-key secondary endpoints of cognition (ADAS-Cog11) and function (ADCS-ADL23), which Athira believes is a</font><font style="color:#222222;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> comprehensive measure of overall disease burden. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Other secondary and exploratory endpoints include changes in plasma biomarkers of neurodegeneration, protein pathology, and neuroinflammation.</font></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Open Label Extension (OLEX) fosgonimeton trial </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">(</font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">NCT04886063</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">)</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Eligible participants who complete the Company&#x2019;s LIFT-AD or ACT-AD clinical trials and elect to participate in the ongoing OLEX are able to receive up to 48 months of open-label treatment.</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Greater than 85% of participants who completed either study have elected to enroll in OLEX to date.</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Currently, more than 65 patients are continuing fosgonimeton treatment beyond 18 months, which is unexpected in a progressive mild-to-moderate Alzheimer&#x2019;s disease population.</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Athira believes the OLEX will complement its long-term safety database and provide insights into fosgonimeton&#x2019;s long-term effects for potentially over four years of investigational treatment.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">SHAPE Phase 2 clinical trial of fosgonimeton in Parkinson&#x2019;s disease dementia and dementia with Lewy bodies </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">(</font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">NCT04831281</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In December 2023, Athira announced encouraging findings from the exploratory SHAPE Phase 2 clinical trial of fosgonimeton for the potential treatment of Parkinson's disease dementia and dementia with Lewy bodies.  </font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Treatment with fosgonimeton 40 mg (n=5) compared to placebo (n=7) showed directional improvements in certain cognitive, functional and biomarker measurements, including ADAS-Cog13, MMSE, and COWAT over the 6-month double-blind treatment period.</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The primary endpoint of the trial, a composite score of the change in Event-Related-Potential (ERP) P300 latency and cognitive assessment (ADAS-Cog13), was not met by protocoled analysis compared with placebo.</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Fosgonimeton was generally well tolerated, with a favorable safety profile. There were no treatment-related serious adverse events observed in the study.  The most common adverse event in the treatment groups was injection site reactions.   </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ATH-1105</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> &#x2013; A next-generation, orally administered, small molecule drug candidate in development for the potential treatment of ALS.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Athira submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for the evaluation of ATH-1105 as a potential treatment for ALS. </font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Athira expects to initiate a first-in-human study of ATH-1105 in the second quarter of 2024.</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ATH-1105&#x2019;s potential is supported by a growing body of preclinical evidence demonstrating statistically significant improvements on nerve and motor function, biomarkers of inflammation and neurodegeneration, and survival in various models of ALS. </font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">These data have been presented at a variety of key scientific and medical meetings including the American Association of Neurology (AAN), the Alzheimer&#x2019;s Association International Congress (AAIC), the Northeast Amyotrophic Lateral Sclerosis Consortium&#174; (NEALS), and the Motor Neurone Disease Association (MNDA).</font></div></div>
  <p style="font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Corporate</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In April 2024, the Company announced the appointment of Javier San Martin, M.D., as Chief Medical Officer. Dr. San Martin is an experienced clinical development executive with a strong track record of advancing therapeutics from early development to approval and through commercialization.  He joins Athira with more than 25 years of drug development experience, most recently as Chief Medical Officer of Arrowhead Pharmaceuticals.  </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Recent Presentations and Publications</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In April 2024, Athira presented a poster at the American Academy of Neurology (AAN) 2024 Annual Meeting, which highlighted preclinical data supporting</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">the continued development of its small molecule candidates targeting the neurotrophic HGF system. The presentation was titled: &#x201c;Targeting Neurotrophic HGF Signaling for the Treatment of Neurodegenerative Disorders.&#x201d; </font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In April 2024, Athira published preclinical data supporting the therapeutic potential of fosgonimeton in Alzheimer&#x2019;s disease in the peer-reviewed journal,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Neurotherapeutics</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">. The original research article is titled: &#x201c;Fosgonimeton attenuates amyloid-beta toxicity in preclinical models of Alzheimer&#x2019;s disease.&#x201d; </font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The findings described several mechanisms by which fosgonimeton may disrupt the neurodegenerative cascade of Alzheimer&#x2019;s disease downstream of A&#x3b2; toxicity, including reduction of mitochondrial oxidative stress and excitotoxicity, improvement of autophagic pathway function, and attenuation of tau hyperphosphorylation.</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In March 2024, Athira presented new clinical and preclinical data further highlighting the therapeutic potential of fosgonimeton at the AD/PD&#153; 2024 International Conference on Alzheimer&#x2019;s and Parkinson&#x2019;s Diseases and Related Neurological Disorders. </font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Results from the exploratory SHAPE Phase 2 clinical trial in Parkinson&#x2019;s disease dementia and dementia with Lewy bodies indicated a favorable safety and tolerability profile for fosgonimeton in trial participants. In addition, changes in ADAS-Cog13 observed in the fosgonimeton 40 mg dose arm were suggestive of a pro-cognitive effect, which was assessed for fosgonimeton for the first time in these disease states.</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In Alzheimer&#x2019;s preclinical disease models, results showed the neuroprotective effects of fosgonimeton against glutamate toxicity in vitro are driven, in part, by activation of pro-survival signaling pathways that may help to counteract neurodegenerative hallmarks of disease such as tau pathology and mitochondrial dysfunction.</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In Parkinson&#x2019;s preclinical disease models, results highlighted the ability of fosgonimeton to mitigate pathological alterations associated with &#x3b1;-synuclein toxicity in vitro and in vivo. </font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In an aged mouse preclinical model of Parkinson&#x2019;s disease that included &#x3b1;-synuclein pathology and GBA1 inhibition, fosgonimeton improved motor function, promoted dopaminergic neuron survival, reduced &#x3b1;-synuclein aggregation, and protected against microglial activation. </font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In February 2024, Athira published research highlighting the neuroprotective and anti-inflammatory effects of ATH-1105 in preclinical models of ALS in the peer-reviewed journal, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Frontiers in Neuroscience. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The original research article is titled: &#x201c;ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, is neuroprotective, preserves neuromotor function, and extends survival in preclinical models of ALS.&#x201d;  </font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">All presentations and publications can be accessed on the Athira website at </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Medical Affairs &#x2013; Athira Pharma</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.  </font></div></div>
  <p style="font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Financial Results</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Cash Position</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">. Cash, cash equivalents and investments were $122.1 million as of March 31, 2024, compared to $147.4 million as of December 31, 2023. Net cash used in operations was $25.8 million for the quarter ended March 31, 2024, compared to $26.2 million for the quarter ended March 31, 2023.<br></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Research and Development (R&amp;D) Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">. R&amp;D expenses were $21.2</font><font style="color:#ff0000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">million for the quarter ended March 31, 2024, compared to $21.3 million for the quarter ended March 31, 2023</font><font style="color:#ff0000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The decrease was driven primarily by decreases in ATH-1020 program costs and personnel costs, partially offset by an increase in other indirect costs. Fosgonimeton program costs for the quarter ended March 31, 2024, were flat compared to the quarter ended March 31, 2023, as decreases in manufacturing and contract research organization costs were offset by increases in program consulting expenses and clinical site visit costs.  <br></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">General and Administrative (G&amp;A) Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">G&amp;A expenses were $6.5</font><font style="color:#ff0000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">million for the quarter ended March 31, 2024, compared to $8.5 million for the quarter ended March 31, 2023</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> The decrease was driven by decreases in legal costs, business development expenses, professional services expenses, personnel costs, and other general corporate expenses.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Net Loss</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">. Net loss was $26.3 million, or $0.69 per share, for the quarter ended March 31, 2024, compared to a net loss of $27.8 million, or $0.73 per share, for the quarter ended March 31, 2023.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About Athira Pharma, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"><br>Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to alter the course of neurological diseases by advancing its pipeline of drug candidates that modulate the neurotrophic HGF system. For more information, visit </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">w</font></font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ww.athira.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">. You can also follow Athira on </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Facebook</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">, </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">LinkedIn</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">, </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">X</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> (formerly known as Twitter) and </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Instagram</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Forward-Looking Statements </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"><br>This communication contains &#x201c;forward-looking statements&#x201d; within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding: Athira&#x2019;s drug candidates as potential treatments for Alzheimer&#x2019;s disease, Parkinson&#x2019;s disease, Parkinson&#x2019;s disease dementia, dementia with Lewy bodies, amyotrophic lateral sclerosis, and other neurodegenerative diseases; future development plans; the anticipated reporting of data; the potential learnings from preclinical studies and other nonclinical data, the ACT-AD and SHAPE trials, and LIFT-AD unblinded interim efficacy and futility analysis and their ability to inform and improve future clinical development plans; expectations regarding the potential efficacy and commercial potential of Athira&#x2019;s drug candidates; and Athira&#x2019;s ability to advance its drug candidates into later stages of development. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as &#x201c;may,&#x201d; &#x201c;will,&#x201d; &#x201c;should,&#x201d; &#x201c;on track,&#x201d; &#x201c;would,&#x201d; &#x201c;expect,&#x201d; &#x201c;plan,&#x201d; &#x201c;believe,&#x201d; &#x201c;intend,&#x201d; &#x201c;pursue,&#x201d; &#x201c;continue,&#x201d; &#x201c;suggest,&#x201d; &#x201c;potential,&#x201d; and similar expressions. Any forward-looking statements are based on management&#x2019;s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the data from preclinical and clinical trials may not support the safety, efficacy and tolerability of Athira&#x2019;s drug candidates; development of drug candidates may cease or be delayed; regulatory authorities could object to protocols, amendments and other submissions; future potential regulatory milestones for drug candidates, including those related to current and planned clinical studies, may be insufficient to support regulatory submissions or approval; Athira may not be able to recruit sufficient patients for its clinical trials; the outcome of legal proceedings that have been or may in the future be instituted against Athira, its directors and officers; possible negative interactions of Athira's drug candidates with other treatments; Athira&#x2019;s assumptions regarding its financial condition and the sufficiency of its cash, cash equivalents and investments to fund its planned operations may be incorrect; adverse conditions in the general domestic and global economic markets; the impact of competition; the impact of expanded drug candidate development and clinical activities on operating expenses; the impact of new or changing laws and regulations; as well as the other risks detailed in Athira&#x2019;s filings with the Securities and Exchange Commission from time to time. These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements. Athira may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the forward-looking statements.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Investor &amp; Media Contact:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Julie Rathbun<br>Athira Pharma<br></font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Julie.rathbun@athira.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"><br>206-769-9219</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Athira Pharma, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Condensed Consolidated Balance Sheets</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">(Amounts in thousands)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.84%;"></td>
    <td style="width:1.46%;"></td>
    <td style="width:1.52%;"></td>
    <td style="width:12.6%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.48%;"></td>
    <td style="width:1.52%;"></td>
    <td style="width:12.58%;"></td>
    <td style="width:1%;"></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;"> </font></p></td>
    <td colspan="3" style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">March 31,</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31,</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">(unaudited)</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#d1f3ff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Assets</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;Cash and cash equivalents</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">77,821</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">90,584</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#d1f3ff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;Short-term investments</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">44,267</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">56,835</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;Other short-term assets</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">6,548</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">7,310</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#d1f3ff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;Other long-term assets</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">4,822</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">5,516</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total assets</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">133,458</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">160,245</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#d1f3ff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Liabilities and stockholders' equity</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;Current liabilities</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">25,598</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">28,840</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#d1f3ff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;Long-term liabilities</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">1,118</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">1,217</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total liabilities</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">26,716</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">30,057</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#d1f3ff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Stockholders' equity</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">106,742</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">130,188</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total liabilities and stockholders' equity</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">133,458</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">160,245</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Athira Pharma, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Condensed Consolidated Statements of Operations and Comprehensive Loss</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="range_a1_e16"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">(Amounts in thousands, except share and per share amounts)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">(Unaudited)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.84%;"></td>
    <td style="width:1.44%;"></td>
    <td style="width:1.5%;"></td>
    <td style="width:12.7%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.32%;"></td>
    <td style="width:1.5%;"></td>
    <td style="width:12.7%;"></td>
    <td style="width:1%;"></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Three Months Ended March 31,</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#d1f4ff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Operating expenses:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:13.7pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:13.7pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Research and development</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">21,236</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">21,293</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#d1f4ff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:13.7pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:13.7pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">General and administrative</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">6,451</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">8,477</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:27.35pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:27.35pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total operating expenses</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="border-top:0.25pt solid #000000;padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="border-top:0.25pt solid #000000;padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">27,687</font></p></td>
    <td style="border-top:0.25pt solid #ffffff03;padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="border-top:0.25pt solid #000000;padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="border-top:0.25pt solid #000000;padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">29,770</font></p></td>
    <td style="border-top:0.25pt solid #ffffff03;padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#d1f4ff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Loss from operations</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(27,687</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(29,770</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Grant income</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#x2014;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">157</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#d1f4ff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Other income, net</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">1,350</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">1,793</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net loss</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(26,337</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(27,820</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#d1f4ff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Unrealized gain on available-for-sale securities</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">212</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">927</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Comprehensive loss attributable to common stockholders</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(26,125</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(26,893</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#d1f4ff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net loss per share attributable to common stockholders,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;basic and diluted</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(0.69</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(0.73</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Weighted-average shares used in computing net loss per</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;share attributable to common stockholders, basic</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;and diluted</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">38,321,573</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">37,923,402</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img247042425_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img247042425_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %8 K4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5CY5R#&Z^O''ZU[?7+4AR2L;0E=!1116904444 %%%% !1110 4444 %%%%
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M -]OY5Z/7G'Q9_X]-/\ ]]OY5I2^-$3^%GEM%%%=YSGM_P .O^1,M/\ >?\
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MPKSSQ6NW7I/=%->AUP7C%-NLJW]Z,5YV:*]#YGHY6[5_D0>%6V^(8!ZJX_\
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M[(3=M6=77G'Q9_X]-/\ ]]OY5W6D7<U_I5M=SQ"*2:,.4!Z9KA?BS_QZ:?\
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M<HTV[IE)S70['5OB#H>G0MY-P+N;'RI%R,^YKA](L+_Q[XG.H7RD6:,"Y_A
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M9U(\LK%1=U<****@H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** ,_6-/74M-E@P-^,H?0UYDRLC%6&&4X(/8UZ[7!>+=/^RZC]I08
MCGY/^]WKR,TH7BJJZ;GKY77M)TGUV+G@N^PTUBYX/SI_6NQKRJPNVL;Z&Y4_
M<;)]QWKU*&59H4E0Y5P"#6F65N>ER/=?D9YG1Y*O.MG^8^BBBO3/,"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DW^HD_P!T_P J
M^?=!_P"1HL/^OI?YU]!2*7C=1W!%>9Z;\-=1LM8MKQ[RW9(IA(0 <D UM2DD
MG<SFFVK'I]%%%8F@5F>(_P#D6-5_Z])?_036G5/5;5K_ $B\LT8*\\#QJ3T!
M((IK<3V/&?AY_P CI9?[K_\ H)KW*O._"_P_O]#U^WU":Z@>.(,"J@Y.1BO1
M*TK24I71---+4IZM_P @>]_ZX/\ R->(^"_^1QT[_KH?Y&O<[V!KFQG@4@-)
M&R GMD8KSW0/AWJ&DZ[:W\MW Z0ON*J#DTZ<DHM,4TVT>DUYK\5-9VQ6VCQ-
MR_[Z;'H/NC^OX"O2:\VUWX?:OK>M7%^][;@2-\H.?E4=!4TK*5V.=[61E^#O
M EOKVE-?7TLT2LY6(1X&0.IKHO\ A56C_P#/W=_F/\*[#2M/CTO2[>RCQMA0
M+D=SW-7*<JLF]&"@K'F'B#X;6>GZ)<WEC/<23PKOV.000.O;TK'^&VL?8/$'
MV-VQ%=C:/]X=*]E=%=&1AE6&"/45Y>_PQU&#4C<V5[ B)+OA!!RHSD"KA44H
MN,V2XV::/4J\.^(O_(YWO^XG_H(KVZ/?Y:>9C?@;L=,]Z\^\4^ +_7=>GOX+
MJ"..0* K Y&!BHHR49:E5$VM#K_#@SX:TX'_ )]T_E7EGCWP\^A:TM_:@K;7
M#;T*_P #]2/ZUZYI-H]AI-K:2,&>&)4)'0D"H==TB'7-(GL9L?.,HW]UAT-$
M)\LK] E&Z,WP9XB7Q!HJN[#[5#A)E[Y['\:Z2O/?#'@C6?#NL)=I>V[0L-DT
M8S\Z_P"->A5-1*_NCC>VIY;\6?\ C[T[_<;^==5\/O\ D3;/ZM_.JWC7PC=>
M)I[5[:>*(0J0=^><UL^&-)ET308+"9U=X\Y9>AR:N4E[-(23YFSBOBKI'_'M
MJT:_],I2/T-<3:B[\2ZU86DSEVPD"G^ZBU[CKVE)K6C7-@^ 9%^5C_"W8UR_
M@_P+-X?U1[V\GBF8)MC" \$]350JI0UW1,H-R.UMX$MK>*",82-0JCV%>%^(
M_P#D>[O_ *^Q_,5[S7F^J_#O4+_Q'/J4=W L<DPD"D'..*FC))NY4TVM#T9?
MN+]*X?XG:Q]CT1-/C;$MVV&QV0=?SKN0,*!Z"O/_ !5X'U3Q%K37BW<"1!0D
M:-G(%33MS78Y7MH<QX*\&P^)(KF>[DECAC(5#'CD]ZZS_A56C_\ /W=_F/\
M"NF\-Z,N@Z)!8@AG49D8?Q,>M:U5.K)RT8HP5M3SK4/A=81:?<26ES<M<(A9
M%8C!([=*X[P1JQT?Q/ 9#MBF/DR ^_\ ]>O=J\QU;X97=SK%S=6-U#%!)(9$
M1@<KGG'YU4*ETU-DRA9WB>FYSTI:K:?'<0Z?;Q73J\Z(%=EZ$CO5FN<U"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K+U^P_M#2I449D3YT^HK4HJ*D%.+B^I=.;A)270\AKO/!]ZUQIC6[Y
M+0-@'_9/2JU]X.6>\>6WN!'&YW%"N<'VK<TK2H-)M?)B)9F.7<]6->3@L)6H
MUKRV_,];&XNC6HVCO^1?HHHKV3Q@HHHH **** "BBB@ HHHH **** "BBB@
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MH\[_ )Z.=S#Z>E;=35J\^B"$+:L****Q- HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>atha-20240515.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-05-15T13:37:33.2513+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://athira.com/20240515" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:atha="http://athira.com/20240515" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="atha-20240515.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139852707984656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 15, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 15,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Athira Pharma, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001620463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-39503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-3368487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">18706 North Creek Parkway<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bothell<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">WA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">98011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">620-8501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATHA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=)L5;%K?ZIR%?.1 WFJNWKDS_ND'VO=^1?@Z%5\'4Z_C-]_FO D.'SZX_()
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M:YBNVKU'V)T8F9?/[@MIC$S+PY@SV*/V OA_*:4YG-C7 =7;G/&_4$L#!!0
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MX_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0
M   ( $>!KU@'04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ 1X&O6#&X<JSN    *P(  !$
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M;',O+G)E;'-02P$"% ,4    " !'@:]8'#AEZC\!   \ @  #P
M    @ &4$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 1X&O6"0>FZ*M
M    ^ $  !H              ( ! !(  'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ 1X&O6&60>9(9 0  SP,  !,
M ( !Y1(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  +Q0
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="atha-20240515.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="atha-20240515.htm">atha-20240515.htm</File>
    <File>atha-20240515.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "atha-20240515.htm": {
   "nsprefix": "atha",
   "nsuri": "http://athira.com/20240515",
   "dts": {
    "inline": {
     "local": [
      "atha-20240515.htm"
     ]
    },
    "schema": {
     "local": [
      "atha-20240515.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20240515.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20240515.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://athira.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0000950170-24-060452-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-060452-xbrl.zip
M4$L#!!0    ( $>!KUCI5)EIX10  .>T   1    871H82TR,#(T,#4Q-2YH
M=&WM/5E7XT;6[_D5->3+-)RA;.V+H7N&T'2&DVZ: ^0DYWO)*:E*6(,L.24)
M\/SZN;<D>6N,66S:!N<AC57[K;O?6U7[_[SM)>1:R#S.TO?O]);VCH@TS'B<
M7KY_=W!^>'S\[I\??MC_&Z7DXZ?C$W(B;LA!6,37XF.<ATF6EU*0[?,O.^0X
M3>)4D#]^/OM,/F9AV1-I02CI%D6_TV[?W-RT>!2G>9:4!8R5M\*LUR:4UIT?
M2L'P._G("D$ZAF985+.I;E_H9L=T.Z;1\C73^H>F=31MK%G6'\CXLEN0[7"'
M8"L8.TU%D@S(ISAE:1BSA)PW@^["+,,6.4@2<H:M<G(F<B&O!6]5?78+  >
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M32<1#(Y51$?7^L5>1>15EWNJ+&*].!ET+N*>R)7*<);U6-I4#+*BR'I0%U=
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M1(4B0\BJ/L?0C05968QO>+6??9GQ,BP (4!TXEL8>;5AU3V6@+@ BUR!7@H
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M^[Y?U?N^<I-[\MH7MPGA;T+X+Q7"WV\'&1]\^&&_W2UZR8?_ 5!+ P04
M" !'@:]8,8G,[PP)  !M:0  $0   &%T:&$M,C R-# U,34N>'-D[5U=<YLX
M%'WOK]#2EW:V&&/7[<93I^/-QXYGTR23I+.=W=GI8)!MIECR"HCM?[\2(()
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M%8[H0N)O=817PK\<<OH_4$L#!!0    ( $>!KUA!4AT4=B8  &,: @ /
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MSLYW"^KXJ3FWDH[]*N,W1T)%0\UH8RQ "]V'\23!DL4?V$C$BPCF.M(E>/(
ME:9WL%4&/.^A&CW,15(W3?]MCNWOC+I+7/(SC\8GI>?U*VXRCY[3V^J \(F!
MT.@ %5T$3U%0X8'"HI @_[, EE6"3W%&_9##V=^IHHXYVC$NM+1]X-#G^("?
MT@^M3FOW^K,,LP*-9A@;= :HB6 &BRK 2 ".*7\*GPT3=0E&V(#[8)RQ'5 .
M=JUV ,@%SX)]AAH!C3VG)'BS@^(T.:RV@=X0'H$BJ9(I N;HDD]U@3) $(0D
M6.=$9=J^J\F64K>RKA$WB@;@*  @3(+$A-#Y+''LM]8D[<,VP+YH%G'\(7=7
MH@0!JG#6!S4)[$ >@V%[O4(SQ]V5*.P@%%>-0";&[7,,?)A%\0E\<1SRZ3%^
M.A^6_2N#R0^F.4?1,PVP5Y&EBV#>*"G#O$/1Z(,8^M[@ Y (QSQ$.KZ4>/#Z
MX>A.$=+-$E$?JCJ- 9)6^V!WW:ZFT@TV8WK.8J,'!KJ/9B2,[Z&;'ZPQ'@O
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M?A!:VBPD0YUK,KU<V[,72^$-%&F= V__\$:9MI+R"^EUKF^:4T<W]?@["CN
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M]1NKL?K_/M?2-_??R#!+1>!$M1/53E2_/%'=:NX?.4'M;!4'@'4GH0/ )P+
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ME$;A;_\/4$L! A0#%     @ 1X&O6.E4F6GA%   Y[0  !$
M ( !     &%T:&$M,C R-# U,34N:'1M4$L! A0#%     @ 1X&O6#&)S.\,
M"0  ;6D  !$              ( !$!4  &%T:&$M,C R-# U,34N>'-D4$L!
M A0#%     @ 1X&O6$%2'11V)@  8QH"  \              ( !2QX  &%T
C:&$M97@Y.5\Q+FAT;5!+!08      P # +L   #N1      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>atha-20240515_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="atha-20240515.xsd" xlink:type="simple"/>
    <context id="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
        </entity>
        <period>
            <startDate>2024-05-15</startDate>
            <endDate>2024-05-15</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf"
      id="F_750cf112-c6ce-4a57-9266-f8e471629b65">0001620463</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf"
      id="F_17f444c2-960c-4f03-8112-8f34fef0c858">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf"
      id="F_c48af838-f186-4bc9-b334-e43df2fb570a">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf"
      id="F_b4a020e8-5153-4f88-98e7-04b881c89c9e">2024-05-15</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf"
      id="F_dff8c163-1823-451e-ab43-d030dd36556c">Athira Pharma, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf"
      id="F_d24a057e-4bd5-4d3f-bd6f-d612bf3f986f">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf"
      id="F_c3fe8820-5adc-4dc9-96c3-614dfad52ce7">001-39503</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf"
      id="F_e78f1d15-e0a1-411b-a117-d17aae3466f6">45-3368487</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf"
      id="F_1c1d385c-f806-4b1f-a337-276b6d6a6c10">18706 North Creek Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf"
      id="F_72a01358-2879-410e-a3f6-d183a6042353">Suite 104</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf"
      id="F_5586779e-1185-4c5a-8a64-daf021d1f8b8">Bothell</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf"
      id="F_033246c2-0b75-480e-b479-0c60d5f842f2">WA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf"
      id="F_3bb5e9ae-fb97-42fd-a935-03038a6c13f7">98011</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf"
      id="F_d6f55983-208f-4f77-928a-c953563d3f07">425</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf"
      id="F_8a5ab1c7-e6ed-4f96-a5fd-e59f66e36108">620-8501</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf"
      id="F_559186fd-8acd-4224-9ef7-7330efd43813">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf"
      id="F_2a184cd2-9cbd-43a1-b57c-235a4cb8a2dd">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf"
      id="F_403f0323-7b93-4e01-8332-c5f927558553">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf"
      id="F_1b5e8d94-039f-4bff-9a83-6723d444d75d">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf"
      id="F_fc20adb2-720f-47a2-b1d4-d871a8e287ab">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf"
      id="F_bd72a9b4-c4cc-472d-9cd9-ecf0f03e0cbc">ATHA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf"
      id="F_e92e58df-0b6e-45ab-8e81-8e34ca27a2d3">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf"
      id="F_507f6bc2-2839-4240-864a-7db7feffcb5b">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_c7fa6c29-71c2-4022-9d3b-76a0224bfbbf"
      id="F_3122370b-eb6d-4013-acfc-c91e493eb9ad">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
